Researchers explored over 100 phosphonoacetic acid compounds to find better antiherpesvirus drugs. Specific structural features are crucial for activity, though some analogs show promise for in vivo use despite lower in vitro efficacy.
Area of Science:
Virology
Medicinal Chemistry
Background:
Phosphonoacetic acid (PAA) is a known selective antiherpesvirus agent.
Developing superior analogs requires understanding structure-activity relationships (SAR).
Purpose of the Study:
To evaluate over 100 PAA congeners in vitro and in vivo.
To identify key structural requirements for antiherpesvirus activity.
To guide the design of improved PAA-based antiviral agents.
Main Methods:
In vitro and in vivo evaluation of over 100 phosphonoacetic acid analogs.
Systematic modification of the PAA structure to assess impact on antiviral activity.
Main Results:
Antiherpesvirus activity demonstrated highly specific structural requirements.
Neither the carboxylic nor the phosphono groups could be replaced without losing activity.
Maintaining the distance between key functional groups was critical; increasing it abolished activity.
Modifications to the methylene carbon reduced but did not eliminate activity.
Shortening the carbon chain to formic acid did not diminish antiherpes activity.
All tested analogs exhibited lower in vitro activity compared to the parent PAA.
Some analogs with reduced in vitro activity possessed favorable in vivo pharmacological properties.
Conclusions:
The antiherpesvirus activity of phosphonoacetic acid is highly dependent on its specific chemical structure.
While no analog surpassed PAA in vitro, some showed potential for in vivo applications due to improved pharmacological profiles.
Further research into PAA analogs could lead to more effective antiherpesvirus therapies.